Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CLM3||EGFR Inhibitor (Pan) 47 RET Inhibitor 39 VEGFR2 Inhibitor 35||CLM3 is an small molecule multi-kinase inhibitor with activity against several kinases including Ret, Vegfr2, and Egfr, which potentially leads to decreased tumor cell growth (PMID: 21459081, PMID: 24423321, PMID: 32055496).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||thyroid gland cancer||sensitive||CLM3||Preclinical||Actionable||In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression in thyroid cancer cells harboring BRAF V600E in culture (PMID: 24423321).||24423321|
|BRAF wild-type||thyroid gland cancer||sensitive||CLM3||Preclinical||Actionable||In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression, in BRAF wild-type thyroid cancer cells in culture (PMID: 24423321).||24423321|
|Unknown unknown||thyroid gland cancer||not applicable||CLM3||Preclinical - Cell line xenograft||Actionable||In a preclinical study, CLM3 induced apoptosis and inhibited EGFR phosphorylation and cell proliferation in human anaplastic thyroid cancer cell lines in culture and inhibited tumor growth in xenograft models (PMID: 24423321).||24423321|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|